意大利内分泌学会与意大利甲状腺协会对2017年美国甲状腺协会妊娠期甲状腺疾病指南的评论:亚临床甲状腺功能减退症的管理
该评论针对2017年美国甲状腺协会(ATA)妊娠期甲状腺疾病指南中关于妊娠期亚临床甲状腺功能减退症的治疗决策流程图进行评论。意大利内分泌学会与意大利甲状腺协会赞同甲状腺过氧化物酶抗体阴性且促甲状腺激素(TSH)在2.5 μIU/mL至参考范围上限之间的孕妇无需治疗,但对TSH在参考范围上限至10.0 μIU/mL的抗体阴性孕妇仅建议考虑治疗表示担忧,并推荐无论甲状腺抗体状态如何,对TSH在该范围的孕妇使用左甲状腺素治疗。
要点
- 赞同甲状腺过氧化物酶抗体阴性且TSH在2.5 μIU/mL至参考范围上限之间的孕妇无需治疗。
- 担忧对甲状腺过氧化物酶抗体阴性且TSH在参考范围上限至10.0 μIU/mL的孕妇仅建议考虑治疗。
- 推荐无论甲状腺抗体状态如何,对TSH在参考范围上限至10.0 μIU/mL的孕妇使用左甲状腺素治疗。
核心结论
- 意大利内分泌学会与意大利甲状腺协会赞同2017年美国甲状腺协会指南中甲状腺过氧化物酶抗体阴性且TSH在2.5 μIU/mL至参考范围上限之间的孕妇无需治疗。
- 该评论担忧对甲状腺过氧化物酶抗体阴性且TSH在参考范围上限至10.0 μIU/mL的孕妇仅建议考虑治疗,并推荐无论甲状腺抗体状态如何,对TSH在该范围的孕妇使用左甲状腺素治疗。
研究设计与样本
- 意大利内分泌学会与意大利甲状腺协会对2017年美国甲状腺协会妊娠期甲状腺疾病指南的评论。
主要发现
- 甲状腺抗体在妊娠期可能出现假阴性,血清阴性慢性自身免疫性甲状腺炎在妊娠期外也是已知的临床实体。
- 2017年美国甲状腺协会指南推荐对甲状腺过氧化物酶抗体阴性且TSH在参考范围上限至10.0 μIU/mL的孕妇仅考虑治疗。
关键数值与推荐
- 对甲状腺过氧化物酶抗体阴性且TSH在2.5 μIU/mL至参考范围上限之间的孕妇无需治疗。
- 对甲状腺过氧化物酶抗体阴性且TSH在参考范围上限至10.0 μIU/mL的孕妇仅考虑治疗。
- 推荐无论甲状腺抗体状态如何,对TSH在参考范围上限至10.0 μIU/mL的孕妇使用左甲状腺素治疗。
临床怎么用
- 根据意大利内分泌学会与意大利甲状腺协会的推荐,对TSH在参考范围上限至10.0 μIU/mL的孕妇,无论甲状腺抗体状态如何,使用左甲状腺素治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2017 American Thyroid Association guidelines for the diagnosis and management of thyroid disease during pregnancy and the postpartum were published six years after the previous ones. They provide comprehensive clinical recommendations for the whole spectrum of thyroid diseases, as well as for optimal iodine intake during pregnancy, postpartum, and lactation. The present position statement mainly regards the recommended flow chart for therapeutic decision making in pregnant women being diagnosed with subclinical hypothyroidism. Here, we comment on the major biochemical and clinical situations and the corresponding therapeutic recommendations. In particular, we welcome the critical revision of the thyrotropin (TSH) reference range in pregnancy, and we agree that there is no need to treat thyroid peroxidase antibody-negative women with a serum TSH ranging from 2.5 μIU/mL to the upper limit of the reference range. This recommendation will hopefully reduce the huge proportion of healthy pregnant women in whom, according to the previous guidelines, levothyroxine therapy had to be initiated. On the other hand, we are concerned with the recommendation to only "consider treatment" in thyroid peroxidase antibody-negative pregnant women with a serum TSH ranging from the upper limit of the reference range to 10.0 μIU/mL. This is because thyroid antibodies may be falsely negative during gestation, and serum negative chronic autoimmune thyroiditis is a well-known clinical entity even outside pregnancy. Based on these and other arguments, we recommend treatment with levothyroxine in pregnant women with TSH levels ranging between the upper limit of the reference range and 10.0 μIU/mL independently from their thyroid antibody status.
引用
- Rotondi M, Chiovato L, Pacini F, et al. Management of Subclinical Hypothyroidism in Pregnancy: A Comment from the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelines-"The Italian Way". Thyroid. 2018. PMID: 29644934. doi:10.1089/thy.2017.0424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。